BioNTech, a prominent player in the bio-tech market, has been making major moves recently challenging Moderna's COVID-19 vaccine patent win and eventually taking over fellow mRNA-based vaccine creator, CureVac, in a $1.25 billion all-stock deal. While BioNTech halts production of its cell therapy manufacturing facilities in Maryland, it continues to focus on expanding its oncology capabilities, embracing promising lung cancer trials alongside Regeneron. Significant steps were also taken to secure partnerships with Bristol Myers for bispecific cancer drugs, settling disputes over COVID-19 vaccine royalties. Despite setbacks such as FDA pauses on their malaria vaccine trial and unfavourable rulings against Pfizer and BioNTech over vaccine patents, the company remains undeterred, soaring ahead with substantial investment pledges of up to £1 billion to bolster the UK's presence, while securing an $11 billion deal with Bristol Myers Squibb for cancer drug collaboration. Entering into numerous clinical trials, such as ones for colorectal and recurrent endometrial cancer, BioNTech establishes itself as a force to be reckoned with in the biotech industry.
BIONTECH News Analytics from Wed, 13 Nov 2024 08:00:00 GMT to Sat, 12 Jul 2025 22:54:00 GMT -
Rating 6
- Innovation 8
- Information 8
- Rumor 3
